Datamonitor, Dec 2010, Pages: 198
and line of therapy.
- Analysis of 10 key brands, including SSRIs, SNRIs, antipsychotics, and novel antidepressants, based upon physician perception and therapeutic role.
- Detailed review of patient
Panel Intelligence, LLC, Oct 2004
oncologists in the United States
This study will help clients understand therapeutic unmet needs and the productattributes and levels of performance that drive physician preference and prescribing behavior
Datamonitor, March 2009, Pages: 185
and the UK
- Analysis of psoriasis population attributes, physicians prescribing decisions, therapy outcomes and treatment satisfaction
- Brand analysis of key pharmaceuticals used in psoriasis, including
GlobalData, Dec 2010, Pages: 66
of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NASH sector. This report is built using data and information sourced from
Global Industry Analysts, Inc., Oct 2011, Pages: 373
. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.
The report profiles 65 companies including many key and niche
Datamonitor, Sep 2010, Pages: 204
effective therapies are needed for the treatment of advanced disease
Research efforts should be directed towards the development of predictive markers and molecular targeted therapy
New product development
Datamonitor, Oct 2008, Pages: 199
to purchase this title
- Targetphysicians more effectively through an understanding of prescribing behavior and its influences.
- Validate new product forecasting based on diagnosis and treatment rates
Datamonitor, Nov 2008, Pages: 362
and disease stage
- Ranking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights of this title
Rituxan
GlobalData, Sep 2011, Pages: 78
. There is a high unmet need which is largely driven by the unavailability of products with adequate efficacy and safety profiles.
Scope
The report provides information on the key drivers and challenges
GlobalData, Dec 2010, Pages: 55
and Unmet Need
3.6 Key Takeaway
4 Ovarian Cancer Therapeutics – Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 ProductProfile for the Major Marketed Products in Ovarian
Datamonitor, Dec 2008, Pages: 189
products need to strongly compete on a lower cost profile by lobbing with IVF payers and need to guarantee supply reliability. In Japan, where physicians prescribe 56% of follicle stimulating hormone and 80
Datamonitor, March 2010, Pages: 124
pipeline treatments.
-Identification of key opportunities and threats facing developers of treatments for spinal cord injury.
-Insight from four internationally recognized key opinion leaders in the field
Life Science Intelligence, Inc., Dec 2011, Pages: 605
resolution and lower target levels than the current standard, thereby identifying diseases earlier in progression
- Next-generation medical devices with anti-fouling surface modifications that reduce the risk
GlobalData, April 2011, Pages: 63
and efficacy profiles which are diseasetargeting.
Strong Pipeline Candidates are expected to Intensify Future Competition
The authors research found that there are currently 20 products in different
GlobalData, June 2011, Pages: 55
attributed to the increase in treatment-seeking behavior and disease awareness and the increasing use of off-label drugs, although no major pipeline products are estimated to be launched in the forecast period
GBI Research, March 2011, Pages: 194
Assessment 23
5 Big Medical Device Companies Turn to Life Sustaining Product Portfolio For Growth 24
5.1 Introduction 24
5.2 Company Profiles 25
5.2.1 Medtronic: 25
5.2.2 Boston Scientific: 25
5.2.3 St Jude
GlobalData, March 2011, Pages: 65
by technologically advanced products possessing improved safety and efficacy profiles which are diseasetargeting. The only available prescription drug, Restasis, has proven its success as is evident by the increasing
Datamonitor, March 2010, Pages: 238
market potential including epidemiology, patient segmentation, unmet needs and targetproductprofiles
Highlights
Despite high cure rates in some forms of leukemia, certain groups of patients still have high unmet
Datamonitor, Dec 2010, Pages: 416
and focus
Datamonitor insight into the disease market
1. Pipeline Overview and Dynamics
Key findings
Pipeline overview
Increase in development candidates as western world focuses on diabetes
Non
Datamonitor, Dec 2010, Pages: 416
antidiabetics
Targetproductprofile versus current level of attainment
4. R&D Approach
Key findings
Clinical trial design in non-insulin antidiabetics
Efficacy
Control of average blood glucose levels
